您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Leriglitazone hydrochloride
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Leriglitazone hydrochloride
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Leriglitazone hydrochloride图片
包装:5mg
规格:98%
市场价:6791元
分子量:408.9

产品介绍
Leriglitazone (Hydroxypioglitazone) hydrochloride,吡格列酮的代谢产物。Leriglitazone (Hydroxypioglitazone) hydrochloride是 PPARγ 激动剂,通过稳定 PPARγ (AF-2) 共激活剂结合表面和增强共激活剂结合能力,提供高转录效力。Leriglitazone (Hydroxypioglitazone) hydrochloride 与 PPARγC (LBD) 结合,其 Ki 值为 1.2 μM,诱导 PPARγ (LBD) 转录效率,EC50 为 680 nM。
货号:ajcx38464
CAS:146062-46-6
分子式:C19H21ClN2O4S
分子量:408.9
溶解度:N/A
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Leriglitazone (Hydroxypioglitazone) hydrochloride, a metabolite of pioglitazone. Leriglitazone (Hydroxypioglitazone) hydrochloride PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone (Hydroxypioglitazone) hydrochloride binds to the PPARγ C-terminal ligand-binding domain (LBD) with a Ki of 1.2 μM,Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC50 of 680 nM[1].

[1]. Mosure SA,et al. Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. J Med Chem. 2019 Feb 28;62(4):2008-2023.